Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3079273 | Neuromuscular Disorders | 2013 | 4 Pages |
Abstract
Slow channel congenital myasthenic syndrome is caused by a genetically determined kinetic anomaly of the acetylcholine receptor at the neuromuscular junction leading to its prolonged open state. Patients typically present with fatigability and static weakness of neck, hand and finger extensors. The open-channel blockers fluoxetine and quinidine have been used as standard treatment, although the former is limited by its side effects. We describe a patient with a novel “de novo” mutation in the α subunit of acetylcholine receptor with clinical and electrophysiological hallmarks of the disease. The patient showed marked treatment response to fluoxetine as well as quinine, a stereoisomer of quinidine, expanding the treatment options for this hereditary disorder.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
Anne-Kathrin Peyer, Angela Abicht, Karl Heinimann, Michael Sinnreich, Dirk Fischer,